“Corticospinal tract microstructural integrity and its correlation with clinical and molecular biomarkers: a profilometry MRI study to identify in-vivo biomarkers of disease severity in ARSACS”- Dr. Sirio Cocozza

Patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) encounter symptoms that affect their walking ability. Among these, they show abnormal tensing of the muscles (spasticity), which partly derives from the disruption of a bundle of fibers...

“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS): A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood” – Drs. Justin Wolter, Matthis Synofzik & David Mengel

It is well established in neurodegenerative diseases that early therapeutic intervention – ideally before neurodegenerative cascades begin to breakdown neuronal function – is key to the success of disease-modifying therapies. Yet we do not understand the...

“Évaluer l’efficacité d’un programme de réadaptation à domicile visant l’amélioration des atteintes motrices, de l’équilibre, de la mobilité, des chutes et des activités courantes chez les personnes atteintes d’ARSACS” – Dre Elise Duchesne

  L’ataxie récessive spastique de Charlevoix-Saguenay (ARSACS) est une maladie incurable caractérisée par plusieurs déficiences motrices progressives apparaissant dès l’enfance. Bien que les atteintes soient majeures, entraînant de grandes difficultés à marcher...